This is a StreetInsider.com Premium Only Page

Radius Health (RDUS) – PRNewswire

Aug 11, 2022 06:42 AM Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 22, 2022 06:24 PM Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Jun 6, 2022 10:54 AM Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 20, 2022 03:57 AM Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology

Dec 8, 2021 12:02 PM Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021

Oct 20, 2021 11:44 AM Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

Jan 5, 2021 08:36 AM Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada

Sep 25, 2020 05:51 AM Radius Health & Menarini Group Provide Elacestrant Update

Jul 23, 2020 05:44 PM Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant